摘要
目的:探讨硫酸镁联合拉贝洛尔对早发型重度子痫前期(EOSPE)患者血清可溶性血管内皮生长因子受体-1(sFlt-1)、非对称性二甲基精氨酸(ADMA)水平的影响。方法:选择2019年1月~2020年12月于某院收治的88例早发型重度子痫前期患者,按随机数字表法分为对照组和观察组各44例,对照组采取硫酸镁注射液,观察组在对照组基础上加用拉贝洛尔。比较两组血压及24h蛋白尿、血清sFlt-1和ADMA水平、母婴结局、不良反应。结果:观察组治疗后收缩压、舒张压及24h蛋白尿分别为(138.33±13.54)mmHg、(94.44±12.53)mmHg、(1.59±0.41)mg,低于对照组的(148.27±13.71)mmHg、(107.78±11.19)mmHg、(2.42±0.38)mg,观察组治疗后的血清sFlt-1、ADMA水平为(2995.28±238.34)pg/ml、(1.76±0.11)μmol/L,低于对照组的(3386.14±268.06)pg/ml、(2.37±0.09)μmol/L,观察组治疗后发生产后出血、胎盘早剥、胎儿窘迫、新生儿窒息总发生率为4.55%,低于对照组的18.18%,有统计学差异(P<0.05);两组不良反应总发生率比较,无统计学差异(P>0.05)。结论:硫酸镁联合拉贝洛尔治疗EOSPE患者疗效确切,可有效调节患者血压、24h蛋白尿,改善血清sFlt-1和ADMA水平,降低不良妊娠结局风险,且不良反应较少。
Objective:To investigate the effect of magnesium sulfate combined with labetalol on serum soluble vascular endothelial growth factor receptor-1(sFlt-1)and asymmetric dimethylarginine(ADMA)levels in patients with early-onset severe preeclampsia(EOSPE).Methods:A total of 88 patients with early-onset severe preeclampsia who were admitted to a hospital from January 2019 to December 2020 were selected and divided into two groups according to the random number table method,with 44 cases in each group.The control group was given magnesium sulfate injection,and the observation group was given labetalol on the basis of the control group.The blood pressure,24h proteinuria,serum sFlt-1 and ADMA levels,maternal and infant outcomes,and adverse reactions were compared between the two groups.Results:The systolic blood pressure,diastolic blood pressure and 24h proteinuria in the observation group after treatment were(138.33±13.54)mmHg,(94.44±12.53)mmHg,and(1.59±0.41)mg,respectively,which were lower than those in the control group[(148.27±13.71)mmHg and(107.78±11.19)mmHg,(2.42±0.38)mg].The serum sFlt-1 and ADMA levels were(2995.28±238.34)pg/ml and(1.76±0.11)μmol/L,which were lower than those in the control group[(3386.14±268.06)pg/ml,(2.37±0.09)μmol/L].The total incidence of postpartum hemorrhage,placental abruption,fetal distress,and neonatal asphyxia in the observation group after treatment was 4.55%,which was lower than 18.18%in the control group,with statistical difference(P<0.05).There was no statistical difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion:Magnesium sulfate combined with labetalol is effective in the treatment of EOSPE patients.It can effectively regulate blood pressure and 24h proteinuria,improve serum sFlt-1 and ADMA levels,and reduce the risk of adverse pregnancy outcomes,with fewer adverse reactions.
作者
马界
武林林
黑倩倩
Ma Jie;Wu Linlin;Hei Qianqian(Xingyang Maternal and Child Health Care Hospital,Henan Province,Zhengzhou 450100)
出处
《数理医药学杂志》
CAS
2021年第12期1793-1795,共3页
Journal of Mathematical Medicine
关键词
早发型重度子痫前期
硫酸镁
拉贝洛尔
血压
24h蛋白尿
可溶性血管内皮生长因子受体-1
非对称性二甲基精氨酸
母婴结局
不良反应
early-onset severe preeclampsia
magnesium sulfate
labetalol
blood pressure
24h proteinuria
soluble vascular endothelial growth factor receptor-1
asymmetric dimethylarginine
maternal and infant outcomes
adverse reactions
